Kancera AB
F:3EE0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kancera AB
F:3EE0
|
SE |
|
A
|
Alphabet Inc
MIL:GOOG
|
US |
|
H
|
HLE Glascoat Ltd
NSE:HLEGLAS
|
IN |
|
S
|
SMIFS Capital Markets Ltd
BSE:508905
|
IN |
|
Roche Holding AG
OTC:RHHBY
|
CH |
|
Marco Polo Marine Ltd
SGX:5LY
|
SG |
|
Metaplanet Inc
OTC:MTPLF
|
JP |
|
Shenzhen Changhong Technology Co Ltd
SZSE:300151
|
CN |
|
S
|
Sealink International Bhd
KLSE:SEALINK
|
MY |
|
A
|
Allied Machinery Co Ltd
SSE:605060
|
CN |
|
Fras Le SA
BOVESPA:FRAS3
|
BR |
|
I
|
ITC Hotels Ltd
NSE:ITCHOTELS
|
IN |
|
Li Auto Inc
HKEX:2015
|
CN |
Kancera AB
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
